Advanced Non-small-cell Lung Cancer Clinical Trial
Official title:
The Fifth Affiliated Hospital of Sun Yat-sen University
Verified date | May 2022 |
Source | Fifth Affiliated Hospital, Sun Yat-Sen University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study is a retrospective study, screening patients with systemic PET / CT scan in our department, enrolling the ones who meet the criteria, collect their information and resting state brain PET images.Then make the brain metabolic network analysis and statistical analysis to explore the PET brain metabolic network of non-small cell lung cancer patients and the effect of chemotherapy drugs on brain metabolic network in patients with advanced lung cancer.
Status | Completed |
Enrollment | 90 |
Est. completion date | February 28, 2021 |
Est. primary completion date | February 28, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Patients with advanced non-small cell lung cancer without any treatment and pathological confirmed non-small cell lung cancer. Exclusion Criteria: - Brain tumors (primary or metastasis), previous surgery, radiotherapy, chemotherapy, stroke, head trauma, psychiatric history (insomnia, depression, mania, schizophrenia and other psychiatric disorders), or history of drug dependence (e. g. sedatives, sleeping pills or sedatives) |
Country | Name | City | State |
---|---|---|---|
China | PET/CT | Zhuhai | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Fifth Affiliated Hospital, Sun Yat-Sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Death | 1-5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05435274 -
Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05192681 -
Tislelizumab as Cross-line Treatment for Advanced NSCLC
|
Phase 2 | |
Active, not recruiting |
NCT05499390 -
AK112 in Advanced Non-Small Cell Lung Cancer
|
Phase 3 | |
Not yet recruiting |
NCT04733521 -
A Phase 1/2 Study of SC-43 in Combination With Cisplatin
|
Phase 1/Phase 2 | |
Recruiting |
NCT04455984 -
Multimodality Treatment Including Curative Resection of Advanced NSCLC
|
||
Recruiting |
NCT05904379 -
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 |